Endovasc Expands Phase I/II Clinical Trials to Renowned French Research Institute; Agreements with Polyclinique d'Essey-les-Nancy.

MONTGOMERY, Texas--(BUSINESS WIRE)--March 17, 1999--Endovasc Ltd. Inc. (OTC BB:ENDV) today announced an expansion of its Critical Limb Ischemia (CLI) therapy program to include doctors and scientists at Polyclinique of Nancy, France. The agreement involves testing the therapeutic effects of its new product, Liprostin(TM), in salvaging limbs that would otherwise be amputated due to peripheral occlusive vascular disease (POVD). POVD is a progressive disease that blocks blood circulation to the extremities, eventually resulting in amputation.

Endovasc Ltd. Inc. will provide Liprostin(TM) adjunctive drug treatment to mechanical intervention with balloon catheter dilation and stent placement to open and maintain blood flow, thus saving the limb. Dr. Michel Henry, FACA, FACC, a prominent French cardiologist, will conduct the clinical trials in France.

"Now that we have funding for these trials, we can accelerate the completion of the Phase I/II trials along the lines suggested by the FDA in our recent preclinical discussion," stated company spokesman, Dr. David P. Summers. "This is a large, though virtually untreated disease, that especially afflicts the elderly."

Endovasc Ltd. Inc. is a biopharmaceutical company using liposomal drug delivery for products that have already shown safety and efficacy in the generic form. The company's products and processes are covered by patents and trade secrets for competing in a $2 billion market.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.